Rediscovering scavenger receptor type BI: surprising new roles for the HDL receptor. Curr Opin Lipidol 2017 Jun;28(3):255-260
Date
03/17/2017Pubmed ID
28301373Pubmed Central ID
PMC5523812DOI
10.1097/MOL.0000000000000413Scopus ID
2-s2.0-85015644706 (requires institutional sign-in at Scopus site) 22 CitationsAbstract
PURPOSE OF REVIEW: Scavenger receptor BI (SR-BI) is classically known for its role in antiatherogenic reverse cholesterol transport as it selectively takes up cholesterol esters from HDL. Here, we have highlighted recent literature that describes novel functions for SR-BI in physiology and disease.
RECENT FINDINGS: A large population-based study has revealed that patients heterozygous for the P376L mutant form of SR-BI showed significantly increased levels of plasma HDL-cholesterol and had increased risk of cardiovascular disease, demonstrating that SR-BI in humans is a significant determinant of cardiovascular disease. Furthermore, SR-BI has been shown to modulate the susceptibility to LPS-induced tissue injury and the ability of sphingosine 1 phosphate to interact with its receptor, linking SR-BI to the regulation of inflammation. In addition, important domains within the molecule (Trp-415) as well as novel regulators (procollagen C-endopeptidase enhancer protein 2) of SR-BI's selective uptake function have recently been identified. Moreover, relatively high expression levels of the SR-BI protein have been observed in a variety of cancer tissues, which is associated with a reduced overall survival rate.
SUMMARY: The HDL receptor SR-BI is a potential therapeutic target not only in the cardiovascular disease setting, but also in inflammatory conditions as well as in cancer.
Author List
Hoekstra M, Sorci-Thomas MAuthor
Mary Sorci Thomas PhD Professor in the Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AnimalsBiomarkers, Tumor
CD36 Antigens
Humans
Inflammation
Molecular Targeted Therapy
Neoplasms
